Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins.
The endocannabinoid (EC) system regulates food intake and energy metabolism. Cannabinoid receptor type 1 (CB1) antagonists show promise in the treatment of obesity and its metabolic consequences. Although the reduction in adiposity resulting from therapy with CB1 antagonists may not account fully for the concomitant improvements in dyslipidemia, direct effects of overactive EC signaling on plasma lipoprotein metabolism have not been documented. The present study used a chemical approach to evaluate the direct effects of increased EC signaling in mice by inducing acute elevations of endogenously produced cannabinoids through pharmacological inhibition of their enzymatic hydrolysis by isopropyl dodecylfluorophosphonate (IDFP). Acute IDFP treatment increased plasma levels of triglyceride (TG) (2.0- to 3.1-fold) and cholesterol (1.3- to 1.4-fold) in conjunction with an accumulation in plasma of apolipoprotein (apo)E-depleted TG-rich lipoproteins. These changes did not occur in either CB1-null or apoE-null mice, were prevented by pretreatment with CB1 antagonists, and were not associated with reduced hepatic apoE gene expression. Although IDFP treatment increased hepatic mRNA levels of lipogenic genes (Srebp1 and Fas), there was no effect on TG secretion into plasma. Instead, IDFP treatment impaired clearance of an intravenously administered TG emulsion, despite increased postheparin lipoprotein lipase activity. Therefore, overactive EC signaling elicits an increase in plasma triglyceride levels associated with reduced plasma TG clearance and an accumulation in plasma of apoE-depleted TG-rich lipoproteins. These findings suggest a role of CB1 activation in the pathogenesis of obesity-related hypertriglyceridemia and underscore the potential efficacy of CB1 antagonists in treating metabolic disease.
Ruby
Maxwell A
MA
Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA.
Nomura
Daniel K
DK
Hudak
Carolyn S S
CS
Mangravite
Lara M
LM
Chiu
Sally
S
Casida
John E
JE
Krauss
Ronald M
RM
D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism*; D001095:Arachidonic Acids / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D063388:Endocannabinoids; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D005989:Glycerides / Q000378:metabolism; D008049:Lipase / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008297:Male; D051379:Mice; D063065:Organophosphonates / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*
D001057:Apolipoproteins E; D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D004791:Enzyme Inhibitors; D005989:Glycerides; D008055:Lipids; D008074:Lipoproteins; D063065:Organophosphonates; D043884:Receptor, Cannabinoid, CB1; D014280:Triglycerides; C094503:glyceryl 2-arachidonate; D002784:Cholesterol; D008049:Lipase
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5780-5
10318961
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9371-6
11470906
Life Sci. 1998;63(8):PL113-7
9718088
Chem Biol. 2007 Dec;14(12):1347-56
18096503
Ann Clin Biochem. 1981 May;18(Pt 3):177-81
7283369
Nat Rev Neurosci. 2003 Nov;4(11):873-84
14595399
Cell Metab. 2007 Apr;5(4):279-91
17403372
JAMA. 2006 Feb 15;295(7):761-75
16478899
Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R345-53
12399252
Nature. 2001 Apr 12;410(6830):822-5
11298451
J Clin Invest. 1998 Feb 15;101(4):905-12
9466986
J Clin Invest. 2005 May;115(5):1298-305
15864349
Biochem Cell Biol. 1986 Aug;64(8):826-35
3768169
Metabolism. 1990 Feb;39(2):155-60
2299988
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4471-5
1584779
J Nutr. 1988 Aug;118(8):932-40
3404286
Eur Heart J. 2008 Jul;29(14):1761-71
18417461
Int J Obes Relat Metab Disord. 2004 Apr;28(4):640-8
14770190
Lancet. 2006 Nov 11;368(9548):1660-72
17098084
Toxicol Sci. 2003 Nov;76(1):131-7
12944586
J Biol Chem. 2006 Jan 13;281(2):934-44
16272564
Clin Chem. 2008 Aug;54(8):1307-16
18515257
Obesity (Silver Spring). 2008 Mar;16(3):553-65
18239598
J Lipid Res. 1998 Aug;39(8):1661-8
9717727
Int J Obes (Lond). 2005 Jul;29(7):755-9
15809662
Proc Natl Acad Sci U S A. 1994 May 10;91(10):4431-5
8183926
JAMA. 2007 Sep 19;298(11):1300-11
17878422
Diabetes. 2006 Nov;55(11):3053-60
17065342
JAMA. 2002 Dec 4;288(21):2709-16
12460094
N Engl J Med. 2005 Nov 17;353(20):2121-34
16291982
J Clin Invest. 2003 Aug;112(3):423-31
12897210
J Clin Invest. 1997 Jun 1;99(11):2672-81
9169497
FASEB J. 2005 Sep;19(11):1567-9
16009704
Cell Metab. 2008 Mar;7(3):227-35
18316028
Chem Rev. 2008 May;108(5):1687-707
18429637
J Lipid Res. 1995 Oct;36(10):2174-84
8576643
Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1006-14
15087308
Nat Chem Biol. 2008 Jun;4(6):373-8
18438404
Diabetes. 2005 Oct;54(10):2838-43
16186383
Lancet. 2005 Apr 16-22;365(9468):1389-97
15836887
J Lipid Res. 2005 Sep;46(9):2023-8
15995182
PLoS One. 2008 Jun 18;3(6):e2503
18560564
J Lipid Res. 2002 Dec;43(12):2136-45
12454276
Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):442-8
16373604